Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity in tumor modeling.

As the FDA phases out animal testing requirements and NIH redirects funding away from animal-only studies, the oncology landscape is transforming. Exciting modalities like ADCs, bispecifics, T-cell engagers demand smarter, more predictive models. CRISPR and AI are accelerating patient-derived model development at unprecedented speed.

This meeting unites industry leaders with cutting-edge vendors to navigate this pivotal shift. Network with pioneers shaping the future of optimizing model selection strategy, discover breakthrough technologies, and position your pipeline ahead of the curve. The industry is evolving; the time is now to be part of the conversation.

URLs:

Tickets: https://go.evvnt.com/3323763-2?pid=91 

Brochure: https://go.evvnt.com/3323763-3?pid=91 

Prices:

Drug Developer Pricing - 2 Day Pass (Conference): USD 0.50,

Academic Pricing - 2 Day Pass (Conference): USD 0.50,

Service Provider Pricing - 2 Day Pass (Conference): USD 3799.00

Speakers: Anlu Chen, Senior Scientist, Computational Oncology, Abbvie, Stephanie Casey Parks, Senior Principal Scientist, Amgen, Deepali Sawant, Scientific Associate Director, Amgen, Bo Hu, Scientist, Bristol Myers Squibb, Yan Qu, Scientist, Translational Oncology, Genentech, Jessica Orf, Principal Scientist II, Gilead Sciences, Barbara Sennino, Vice President, Early Development, 3T Biosciences, Timothy Sproul, Director, Atomic AI, Paul Ponath, Principal Scientist, Bolt Biotherapeutics, Nadege Morisot, Director, In Vivo Translational Biology, Earli, Janica Wong, Director, Therapeutic Biology, Generate:Biosciences, Aditi Bapat, Scientist, Discovery, Pheast Therapeutics, Marini Thian, Associate Director, Toxicology, Revolution Medicines, Udaya Rangaswamy, Director, Translational Biology, Rondo Therapeutics, Renu Dhanasekaran, Professor, Stanford University, Nichole Escalante, Senior Scientist and Group Lead, In Vivo Pharmacology and PK, Zymeworks